Filter by content type
Filter by content year
Filter by form group
Filter by type
Filter by tags
Filter by gallery
Filter by category
Filter by category
Filter by category
Filter by category
Biogen to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
December 19, 2023 - … treatment for Friedreich’s ataxia. Biogen is advancing a pipeline of potential novel therapies across neurology, … treatment for Friedreich’s ataxia. Biogen is advancing a pipeline of potential novel therapies across neurology, … treatment for Friedreich’s ataxia. Biogen is advancing a pipeline of potential novel therapies across neurology, …
Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission
December 19, 2023 - … treatment for Friedreich’s ataxia. Biogen is advancing a pipeline of potential novel therapies across neurology, … Eisai; the potential of Biogen's commercial business and pipeline programs; and risks and uncertainties associated … treatment for Friedreich’s ataxia. Biogen is advancing a pipeline of potential novel therapies across neurology, …
CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease
December 15, 2023 - … treatment for Friedreich’s ataxia. Biogen is advancing a pipeline of potential novel therapies across neurology, … ataxia; the potential of Biogen’s commercial business and pipeline programs, including Friedreich’s ataxia; and risks … treatment for Friedreich’s ataxia. Biogen is advancing a pipeline of potential novel therapies across neurology, …
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
December 14, 2023 - … treatment for Friedreich’s ataxia. Biogen is advancing a pipeline of potential novel therapies across neurology, … the potential of Biogen’s commercial business and pipeline programs, including ZURZUVAE; the anticipated … treatment for Friedreich’s ataxia. Biogen is advancing a pipeline of potential novel therapies across neurology, …
“LEQEMBI® Intravenous Infusion” (Lecanemab) for the Treatment of Alzheimer’s Disease to be Launched in Japan on December 20
December 12, 2023 - … treatment for Friedreich’s ataxia. Biogen is advancing a pipeline of potential novel therapies across neurology, … Eisai; the potential of Biogen's commercial business and pipeline programs, including LEQEMBI; and risks and … treatment for Friedreich’s ataxia. Biogen is advancing a pipeline of potential novel therapies across neurology, …
Biogen to Participate in the 6th Annual Evercore ISI HealthCONx Conference
November 16, 2023 - … treatment for Friedreich’s ataxia. Biogen is advancing a pipeline of potential novel therapies across neurology, … treatment for Friedreich’s ataxia. Biogen is advancing a pipeline of potential novel therapies across neurology, … treatment for Friedreich’s ataxia. Biogen is advancing a pipeline of potential novel therapies across neurology, …
Biogen Appoints Monish Patolawala to its Board of Directors
November 6, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … of, and expectations for, our commercial business and pipeline programs; capital allocation and investment … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On Alzhe
October 25, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … Eisai; the potential of Biogen's commercial business and pipeline programs, including LEQEMBI; and risks and … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease
October 25, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … study; the potential of Biogen's commercial business and pipeline programs; and risks and uncertainties associated … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting
October 19, 2023 - … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, … Eisai; the potential of Biogen's commercial business and pipeline programs, including LEQEMBI; and risks and … pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, …
